Gamida Cell Ltd.
Harey Yehuda 54
P.O.B. 94
Savyon
56530
Tel: 03-534-7482
Fax: 03-534-3067
195 articles with Gamida Cell Ltd.
-
Gamida Cell Announces Changes to Board of Directors
3/20/2023
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum.
-
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
3/20/2023
Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Monday, March 27, 2023, at 8:00 a.m. ET to review its fourth quarter and full year 2022 financial results and provide an update on the company.
-
Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
3/7/2023
Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference.
-
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
2/18/2023
Gamida Cell Ltd. announced that two oral presentations and a poster presentation highlighting Gamida Cell’s investigational product candidates, omidubicel and GDA-201, were shared at the 2023 Tandem Meetings, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy, and the Center for International Blood and Marrow Transplant Research.
-
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
12/12/2022
Gamida Cell Ltd. announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”).
-
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
11/23/2022
Gamida Cell Ltd. today announced that members of the management team will present at the following upcoming investor conferences.
-
Gamida Cell Provides Regulatory Update on Omidubicel
11/21/2022
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent interactions with the U.S. Food and Drug Administration (FDA) relating to the company’s Biologics License Application (BLA) for omidubicel, the company’s advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant.
-
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
11/14/2022
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022.
-
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
11/10/2022
Gamida Cell Ltd. today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the Jefferies London Healthcare Conference, November 17, 2022 with a presentation at 9:10 a.m. GMT.
-
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
11/7/2022
Gamida Cell Ltd. (Nasdaq: GMDA) today announced encouraging preclinical data on GDA-501, a genetically modified NAM (nicotinamide) Natural Killer (NK) pre-clinical cell therapy candidate from Gamida Cell’s expanding pipeline of cell therapy candidates.
-
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
11/7/2022
Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Monday, November 14, 2022, at 8:00 AM EST to review its third quarter 2022 financial results and provide an update on the company.
-
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
11/3/2022
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematological and solid cancers and other serious diseases, today announced an oral presentation of a real-world analysis comparing the effectiveness of omidubicel to other allo-HCT donor sources from the Center for International Blood and Marrow Transplant Research (CIBMTR) database.
-
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
10/10/2022
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa.
-
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
9/29/2022
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting.
-
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
9/28/2022
Gamida Cell Ltd. announced that it has entered into a Commitment Letter with certain funds managed by Highbridge Capital Management, LLC, pursuant to which Highbridge has committed to provide a $25 million senior secured, convertible term loan.
-
Gamida Cell Announces Launch of Public Offering of Ordinary Shares - September 27, 2022
9/27/2022
Gamida Cell Ltd., the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the launch of a follow-on public offering of its ordinary shares.
-
Seven biopharma companies are under new leadership. This week's Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future.
-
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
9/19/2022
Gamida Cell Ltd. today announced that Abigail “Abbey” L. Jenkins, MS, has joined as President & CEO.
-
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
9/12/2022
Gamida Cell Ltd. today announced the presentation of data supporting the potential of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant at the 2022 Cord Blood Connect Meeting, being held in South Beach, Florida.
-
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
8/15/2022
Gamida Cell today provided a business update and reported financial results for the quarter ended June 30, 2022.